

# Phase 1 Dose Escalation Study of PRS-343, a HER2/4-1BB Bispecific Molecule, in Patients with HER2+ Malignancies

Sarina Piha-Paul<sup>1</sup>, Johanna Bendell<sup>2</sup>, Anthony Tolcher<sup>3</sup>, Sara Hurvitz<sup>4</sup>, Amita Patnaik<sup>5</sup>, Anuradha Krishnamurthy<sup>6</sup>, Rachna Shroff<sup>7</sup>, Paula Pohlmann<sup>8</sup>, Noah Hahn<sup>9</sup>, Markus Zettl<sup>10</sup>, Jian Mei<sup>10</sup>, Kayti Aviano<sup>10</sup>, Manuela Duerr<sup>10</sup>, Rushdia Yusuf<sup>10</sup>, Louis A Matis<sup>10</sup>, Shane Olwill<sup>10</sup>, Ingmar Bruns<sup>10</sup>, Geoffrey Ku<sup>11</sup>

<sup>1</sup>The University of Texas MD Anderson Cancer Center, Texas, USA <sup>2</sup>Sarah Cannon Research Institute, LLC, Tennessee, USA <sup>3</sup>NEXT Oncology, Texas, USA <sup>4</sup>University of California Los Angeles Jonsson Comprehensive Cancer Center, California, USA

<sup>5</sup>South Texas Accelerated Research Therapeutics, Texas, USA <sup>6</sup>University of Pittsburgh Medical Center, Pennsylvania, USA <sup>7</sup>University of Arizona Cancer Center, Arizona, USA <sup>8</sup>Georgetown University Hospital. Washington DC. USA

<sup>9</sup>Sydney Kimmel Cancer Center at Johns Hopkins, Maryland, USA

<sup>10</sup>Pieris Pharmaceuticals, Inc., Massachusetts, USA
<sup>11</sup>Memorial Sloan Kettering Cancer Center, New York, USA



#### **Disclosures**



### **Geoffrey Ku**

Reports relationships with the following:

- Arog Pharmaceuticals research support
- AstraZeneca research support, consulting
- Bristol-Myers Squibb research support, consulting
- Daiichi Sankyo research support
- Eli Lilly consulting
- Merck research support, consulting
- Pieris Pharmaceuticals research support, consulting
- Zymeworks research support

#### **Study sponsored by Pieris Pharmaceuticals**




#### PRS-343: A HER2 4-1BB Bispecific



HER2-targeting moiety of the drug localizes to the tumor microenvironment and facilitates 4-1BB cross-linking

4-1BB cross-linking ameliorates T-cell exhaustion and is critical for T-cell expansion





#### **Study Design**



#### **Primary Objectives**

- Characterize safety profile
- Identify MTD or RP2D

#### **Secondary Objectives**

- Characterize PK profile
- Investigate dosing schedule
- Assess potential immunogenicity and PD effects
- Investigate efficacy

Active schedules

Schedule 1: Q3W dosing on Day 1 Schedule 2: Q2W dosing on Days 1, 15

#### **Current Enrollment**

Dose Level	No. Patients	Dose (mg/kg)
1	1	0.0005 (Q3W)
2	1	0.0015
3	1	0.005
4	2	0.015
5	2	0.05
6	5	0.15
7	7	0.5
8	6	1
9	6	2.5
10	9	5
11	7	8
11b	6	8 (Q2W)
Total	53	

Data cut-off: 23-Oct-19 for subjects up to Cohort 11b; additional cohorts enrolling



#### **Key Enrollment Criteria**



#### **Inclusion Criteria**

- Diagnosis of HER2+ advanced/metastatic solid tumor malignancy that has progressed on standard therapy or for which no standard therapy is available
- HER2+ solid tumors documented by ASCO, CAP or institutional guidelines
- Patients with breast, gastric and GEJ cancer must have received at least one prior HER2-targeted therapy for advanced / metastatic disease
- Measurable disease per RECIST v1.1
- ECOG 0 or 1
- Adequate liver, renal, cardiac and bone marrow function

#### **Exclusion Criteria**

- Ejection fraction below the lower limit of normal with trastuzumab and/ or pertuzumab
- Systemic steroid therapy or any other form of immunosuppressive therapy within seven days prior to registration
- Known, symptomatic, unstable or progressing CNS primary malignancies
- Radiation therapy within 21 days prior to registration (limited field radiation to non-visceral structures is allowed, e.g., limb bone metastasis)



### **Baseline Characteristics** All Subjects (n = 53)



Characteristic	n (%)
Age, Median (range)	61 (29–92)
Gender	
F	33 (62%)
M	20 (38%)
ECOG PS	
0	12 (23%)
1	41 (77%)
Prior Therapy Lines	
1	6 (11%)
2	5 (9%)
3	11 (21%)
4	10 (19%)
5+	21 (40%)
Median no. of anti-HER2 Treatments	
Breast	4
Gastric	2


Primary Cancer Type	n (%)		
Gastroesophageal	19 (36%)		
Breast	14 (26%)		
Gynecological	6 (11%)		
Colorectal	5 (9%)		
Gallbladder/ Biliary	4 (8%)		
Bladder	2 (4%)		
Pancreatic	1 (2%)		
Other – Salivary Duct	1 (2%)		
Other – Melanoma	1 (2%)		

Data cut-off: 23-Oct-19



#### **PRS-343 Clinical Pharmacology**





### Preliminary PRS-343 Pharmacology Profile

- Preliminary PK: Mean terminal half-life of PRS-343 is approximately five days
- 27.8% of patients are ADA+ with titers above 1:150 in cohorts covering active dose range (≥2.5 mg/kg)

Note: PRS-343 concentrations are below limit of quantification for dose levels < 0.015 mg/kg



### **Treatment-Related Adverse Events All Subjects**



Occurred in ≥ 1 Patient	n = 111   n (%)	% Grade 3	
Infusion Related Reaction	10 (9%)	2 (2%)	
Fatigue	10 (9%)	1 (1%)	
Chills	7 (6%)	0	
Flushing	7 (6%)	3 (3%)	
Nausea	7 (6%)	0	
Diarrhea	7 (6%)	0	
Vomiting	6 (5%)	0	
Non-Cardiac Chest Pain	5 (4%)	1 (1%)	

No Grade 4 or 5 Treatment-Related AEs



### **Summary of Responses at Active Dose Range of PRS-343**




### Based on clinical data, serum concentration of > 20 $\mu$ g/ml defines active dose range (beginning at Cohort 9)

Cohort	11b	11	10	9	Total	
Best Response	8 mg/kg, Q2W	8 mg/kg, Q3W	5 mg/kg, Q3W	2.5 mg/kg, Q3W	Total	
Response Evaluable Patients	5	4	4	5	18	
PR	2	-	-	-	2	
SD	3	2	1	2	8	
PD	-	2	3	3	8	
ORR	40%	0%	0%	0%	11%	
DCR	100%	50%	25%	40%	55%	



### **Best Response in Target Lesions Monotherapy Study Cohorts 1-11b**








### **Best Response in Target Lesions Monotherapy Study Cohorts 9-11b**








### Average Time on Treatment with PRS-343 Significantly Increases in Cohort 11b (8 mg/kg Q2W)









### Increased CD8<sup>+</sup> T Cell Numbers in Tumor Biopsies Post-Treatment









Pronounced increase in CD8<sup>+</sup> T cell numbers is observed post-treatment in patients receiving doses ≥ 2.5 mg/kg

Patients benefiting from treatment (SD > 120 days (blue) and PR (green) had more pronounced increase in CD8<sup>+</sup>T cell number in tumor vs. stroma



### Gastric Cancer Patient with Confirmed PR Patient Profile, Treatment History and RECIST



#### **Patient Profile**

- Cohort 11b | 8 mg/kg every two weeks
- 80-year old woman; initial diagnosis on June 2017
- Stage IV gastric adenocarcinoma
- Metastases to liver, lymph node and adrenal glands
- HER2 IHC 3+; PD-L1 positive (CPS=3)
- NGS: ERBB2 amplification, TP53 mutation, alteration of CDK12 and SF3B1

Oncology Treatment History	Duration	Best Response
Trastuzumab, Pembrolizumab + Capecitabine/oxaliplatin	July 2017 – June 2018	Stable Disease
Nivolumab with IDO1 inhibitor (investigational drug)	Aug 2018 – Jan 2019	Stable Disease

Losione Losion Cita		Lesion Size (mm)				
Lesions	Lesions Lesion Site	Baseline	C2 Post-treatment	C3 Post-treatment	C4 Post-treatment	C6 Post-treatment
Target 1	Liver	14	12	10	9	9
Target 2	Liver	20	16	10	8	8
Target 3	Pancreas	19	16	14	14	14
% Change from Baseline			-17%	-36%	-42%	-42%


PR, partial response; HER2, human epidermal growth factor receptor 2; PD-L1, Programmed Death Ligand 1; CPS, combined positive score; NGS, next-generation sequencing




### **Gastric Cancer Patient with Confirmed Partial Response**




**Baseline** 





Cycle 4









### **CD8+ T Cell Numbers Increase Post-Treatment** in Responding Gastric Cancer Patient







Pre-Treatment (CD8: Teal | Ki67: Red)



Post-Treatment (CD8: Teal | Ki67: Red)





CD8+ T cell numbers increase post-treatment. This is more pronounced in tumor tissue, consistent with the predicted MoA of PRS-343.



#### **Conclusions: PRS-343 as Monotherapy**



Well-tolerated, with a good safety profile in all doses and schedules tested

Demonstrated anti-tumor activity in heavily pre-treated patient population across multiple tumor types; treatment history indicative of 4-1BB-driven mechanism-of-action

Showed a clear increase in CD8<sup>+</sup> T cell numbers and proliferative index in the tumor microenvironment of responders

Future studies are planned for continued development in defined HER2+ indications



#### **Acknowledgements**



- Patients, their families and caregivers
- Investigators, as well as their site personnel
  - The University of Texas MD Anderson Cancer Center S. Piha-Paul, B. Bruggman
  - Sarah Cannon Research Institute, LLC J. Bendell, J. Costin
  - NEXT Oncology A. Tolcher, K. Dotson
  - University of California Los Angeles Jonsson Comprehensive Cancer Center S. Hurvitz, M. Rocha, R. Rubin
  - South Texas Accelerated Research Therapeutics A. Patnaik, K. Rivas
  - University of Pittsburgh Medical Center A. Krishnamurthy, B. Foster, A. Blasko
  - University of Arizona Cancer Center R. Shroff, D. Pennington
  - Georgetown University Hospital P. Pohlmann, S. Wagner
  - Sydney Kimmel Cancer Center at Johns Hopkins N. Hahn, E. Lee
  - Memorial Sloan Kettering Cancer Center G. Ku, T. Shrivastav, P. Collins



## Appendix

### **Adverse Events Unrelated to Treatment All Subjects**



Adverse Events Unrelated to Treatment	n = 303   n (%)
Fatigue	14 (5%)
Abdominal pain	11 (4%)
Anemia	10 (3%)
Constipation	9 (3%)
Decreased appetite	9 (3%)
Dyspnea	9 (3%)
Diarrhea	7 (2%)
Dysphagia	6 (2%)
Nausea	6 (2%)

Adverse Events Unrelated to Treatment	n = 303   n (%)	
Alanine aminotransferase increased	5 (2%)	
Blood bilirubin increased	5 (2%)	
Headache	5 (2%)	
Hyperglycemia	5 (2%)	
Pain	5 (2%)	
Pruritus	5 (2%)	
Vomiting	5 (2%)	
Weight decreased	5 (2%)	

